Medicaid Drug Spending: Navigating Rising Costs and New Federal Initiatives
Medicaid prescription drug spending has seen substantial growth in recent years, fueled by both the emergence of innovative, high-cost medications – including GLP-1s and cell and gene therapies – and overall increases in healthcare utilization. While rebates help offset these costs, the landscape is shifting with new federal initiatives aimed at lowering prices and expanding access. This analysis explores recent trends, the impact of these changes, and what the future may hold for Medicaid drug spending.
The Surge in Spending: A Closer Look at the Numbers
Net spending on prescription drugs within Medicaid climbed from $31 billion in fiscal year 2019 to $46 billion in fiscal year 2024, representing a 46% increase. This growth isn’t solely due to increased prescription volume; the number of prescriptions filled only rose by 2% over the same period. Instead, the rise is largely driven by the increasing cost of specialty drugs, particularly those used to treat rare diseases, cancer, and conditions like obesity and diabetes. From FY 2023 to FY 2024, rebates grew, resulting in a 10% decrease in net spending.
Net spending per prescription increased by 42% (from $43 to $61), and net spending per enrollee rose by 25% (from $481 to $603) during this timeframe. Despite this substantial increase, prescription drug spending still accounts for approximately 6% of total Medicaid spending, a figure that has remained relatively stable for the past two decades.
The Power of Rebates and State Negotiations
Rebates play a crucial role in mitigating Medicaid drug costs, reducing gross spending by over half. State supplemental rebates – negotiated directly between states and manufacturers – are becoming an increasingly significant component of these savings. Recent data suggests states are actively expanding these negotiations to combat rising drug prices.
The recently announced federal models aim to build on this by negotiating additional supplemental rebates, though the extent to which these “most-favored nation” (MFN) prices will compare to existing state-negotiated net prices remains unclear.
Federal Initiatives: A Multi-Pronged Approach
The Trump administration has launched several initiatives to address prescription drug costs within Medicaid. These include:
- “Most-Favored Nation” (MFN) Drug Pricing: Agreements with manufacturers to provide MFN pricing in Medicaid and introduce new medications at these prices.
- New CMS Innovation Center (CMMI) Models: The GENEROUS model, offering supplemental rebates based on prices in other countries, and the BALANCE model, focused on expanding access to obesity drugs through negotiated GLP-1 prices. Both models are voluntary for states and manufacturers.
- TrumpRx: A website launched in early February 2026 offering discounted prices on brand-name medications for cash-paying patients.
These initiatives are intended to lower costs for both Medicaid programs and individuals, but details of the agreements remain largely confidential, making it difficult to fully assess their impact.
Shifting Enrollment and Future Trends
Recent quarterly data reveals a concerning trend: declining Medicaid enrollment and prescription numbers alongside continued elevated gross spending. This is likely linked to the unwinding of the continuous enrollment provision implemented during the COVID-19 pandemic. As more individuals lose Medicaid coverage, access to affordable medications may grow a significant challenge.
The 2025 reconciliation law, signed by President Trump, is also expected to result in Medicaid funding cuts and coverage losses, potentially exacerbating these challenges. While TrumpRx offers discounts for cash-paying patients, these costs may still be prohibitive for low-income individuals who have lost Medicaid coverage.
What’s on the Horizon?
Looking ahead, several factors will shape Medicaid prescription drug trends:
- Implementation of Federal Initiatives: The success of the MFN pricing agreements and the CMMI models will depend on state and manufacturer participation and the specifics of the negotiated rebates.
- Enrollment Trends: Continued declines in Medicaid enrollment could impact prescription volume and overall spending.
- Drug Pipeline: The introduction of new, high-cost specialty drugs will continue to exert upward pressure on spending.
- Rebate Strategies: States will likely continue to prioritize and expand supplemental rebate negotiations.
The interplay of these factors will determine whether Medicaid can effectively manage rising drug costs and ensure access to essential medications for its enrollees.
FAQ
Q: What are GLP-1s?
A: GLP-1s are a class of drugs originally developed for diabetes treatment, but also used for weight loss and cardiovascular risk reduction.
Q: How do rebates affect Medicaid drug spending?
A: Rebates significantly reduce the net cost of prescription drugs for Medicaid, offsetting over half of gross spending.
Q: What is TrumpRx?
A: TrumpRx is a website offering discounted prices on brand-name medications for cash-paying patients.
Q: Will these changes impact current Medicaid enrollees?
A: The impact on current enrollees is complex. While some initiatives aim to lower costs, potential funding cuts and coverage losses could create barriers to access.
Q: What is the GENEROUS model?
A: GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) is a voluntary model through which CMS will negotiate supplemental drug rebates based on prices paid in other countries.
Did you know? State supplemental rebates now make up an increasing share of all Medicaid drug rebates, demonstrating the growing importance of state-level negotiations.
Pro Tip: Stay informed about changes to your Medicaid coverage and explore available resources, such as TrumpRx, to potentially lower your prescription drug costs.
Reader Question: What resources are available to help me understand my prescription drug benefits?
To learn more about Medicaid drug coverage and recent changes, visit the Medicaid.gov website or contact your state’s Medicaid agency.
Share your thoughts on these changes in the comments below! Explore our other articles on healthcare policy and prescription drug costs for more in-depth analysis.
